


Large variation in lipid reduction with high-dose statin tx

31 July 2014



were subject to large interindividual variability despite a fixed statin dose. More than 40 percent of those assigned to high-dose statins did not achieve an LDL-C target of

There is considerable interindividual variation in the magnitude of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B reductions achieved with statin therapy, which affects cardiovascular disease risk, according to a study published in the August 5 issue of the *Journal of the American College of Cardiology*.

(HealthDay)—There is considerable interindividual variation in the magnitude of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) reductions achieved with statin therapy, which affects cardiovascular disease risk, according to a study published in the August 5 issue of the *Journal of the American College of Cardiology*.

S. Matthijs Boekholdt, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues conducted a meta-analysis using individual patient data from eight randomized controlled statin trials. Data were included for 38,153 patients who were allocated to [statin therapy](#), and underwent assessment for conventional lipids and apolipoproteins at baseline and at one-year follow-up.

The researchers found that 5,287 participants had 6,286 major cardiovascular events during follow-up. Reductions of LDL-C, non-HDL-C, and apoB

APA citation: Large variation in lipid reduction with high-dose statin tx (2014, July 31) retrieved 2 May 2021 from <https://medicalxpress.com/news/2014-07-large-variation-lipid-reduction-high-dose.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.